Ambulatory patients with symptomatic heart failure (HF) events, without cardiac implantable electronic devices (CIEDS), who receive an insertable cardiac monitor (ICM) do not have additional arrhythmia burden modification when undergoing congestion management versus standard care, a sub-analysis of the ALLEVIATE-HF trial shows.